Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowBarclays has downgraded the stock rating for Terns Pharmaceuticals, citing the recent deal with Merck. This change could influence investor sentiment and trading volumes for Terns Pharmaceuticals as the market reacts to the adjustment in outlook. The specifics of the rating change were not disclosed in the report. Analyst ratings can significantly impact stock prices and market positioning.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Merck & Co. Inc. (MRK)
Merck is a global pharmaceutical company best known for its oncology, vaccine, and animal-health franchises.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRK news
- Halozyme Therapeutics Projects $1.7β$1.8 Billion Revenue Growth in 2026
- Merck's Winrevair Meets Primary Endpoint in Heart Failure Trial Results
- Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals
- Merck Pursues $6 Billion Acquisition of Terns Pharma, Reports FT
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
